Amiens and Toulouse, France
From the Department of Plastic Reconstructive and Aesthetic Surgery, University Hospital of Picardie, Amiens Picardie University Hospital; the Department of Plastic, Reconstructive and Aesthetic Surgery, CHRU Rangueil; and the Department of Epidemiology, Health Economics and Public Health, UMR1027 INSERM-Université de Toulouse III, Centre Hospitalier Universitaire de Toulouse.
Received for publication December 6, 2017; accepted July 20, 2018.
This trial is registered under that name “Botulinum Toxin for Treatment of Migraine: A Meta-Analysis,” PROSPERO identification number CRD42016048772 (http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016048772).
Disclosure:None of the authors has a financial interest in any of the products, devices, or drugs mentioned in this article.
Benoit Chaput, M.D., Plastic and Reconstructive Surgery Unit, CHU Rangueil, 1, Avenue Jean Poulhès, Toulouse, France, [email protected]